Cogstate Releases Online Cognitive Screening Solution for Alzheimer's Trial
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments
Cogstate, a cognitive science and medical technology company, announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:
- Functionality allowing pre-screened participants to select an investigator site in their area, with automatic site notification for a more seamless enrolment process.
- The ability to deploy the solution in many different languages, as required for global clinical trials
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
